SCHEMBL1971695

SCHEMBL1971695

COC(=O)c1sc(Br)cc1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
HSD17B10 Q99714 2/20 0.41
KMT2A Q03164 2/20 0.41
TSHR P16473 1/20 0.41
LCK P06239 1/20 0.41
FYN P06241 1/20 0.41
TRPM8 Q7Z2W7 1/20 0.40
NPSR1 Q6W5P4 3/20 0.38
PPARG P37231 1/20 0.38
NCOA1 Q15788 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
KDM4E B2RXH2 4/20 0.38
DAO P14920 1/20 0.37
ALDH1A1 P00352 3/20 0.37
LMNA P02545 2/20 0.37
AKR1C3 P42330 1/20 0.37
AKR1C2 P52895 1/20 0.37
GSK3B P49841 1/20 0.37
MAPK1 P28482 2/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1971697 0.89 MAPT (0.44) MAPTHSD17B10KMT2ATSHRNPSR1
SCHEMBL1973369 0.86 ALDH1A1 (0.40) MAPTHSD17B10KMT2ATSHRLCK
SCHEMBL1974281 0.81 GSK3B (0.44) KMT2ATSHRLCKFYNKDM4E
SCHEMBL28383354 0.79 GSK3B (0.40) MAPTHSD17B10KMT2ATSHRLCK
SCHEMBL319034 0.79 GSK3B (0.53) MAPTHSD17B10KMT2ATSHRNPSR1
SCHEMBL28175473 0.79 DAO (0.53) MAPTHSD17B10KMT2ATSHRTRPM8
SCHEMBL2730725 0.78 MAPT (0.44) MAPTHSD17B10KMT2ATSHRNPSR1
SCHEMBL1374020 0.78 TSHR (0.44) MAPTHSD17B10KMT2ATSHRTRPM8
SCHEMBL1371646 0.76 KMT2A (0.42) MAPTHSD17B10KMT2ATSHRLCK
SCHEMBL102283 0.76 KDM4E (0.53) MAPTHSD17B10KMT2ATSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000006-B2 Thienopyridine compounds, and methods of use thereof FIBROGEN, INC. (US) 2015-04-07 US disclosed
US-20140221422-A1 NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2014-08-07 US disclosed
US-8703795-B2 Thienopyridine compounds, and methods of use thereof FIBROGEN, INC. (US) 2014-04-22 US disclosed
EP-1866318-B1 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN INC (US) 2011-06-22 EP disclosed
EP-1866318-A2 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2007-12-19 EP disclosed
WO-2006094292-A2 THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2006-09-08 WO disclosed
US-20060199836-A1 Novel thienopyridine compounds, and methods of use thereof FIBROGEN, INC. 2006-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221422-A1 NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN2 MAPT 3256/4885HSD17B10 3718/4885KMT2A 1140/4885
US-20060199836-A1 Novel thienopyridine compounds, and methods of use thereof HIF1AN, HIF1A, EGLN2 MAPT 3256/4885HSD17B10 3718/4885KMT2A 1140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.